All Updates

All Updates

icon
Filter
Product updates
SOPHiA GENETICS launches residual acute myeloid application for post-remission monitoring
Precision Medicine
Jun 24, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 24, 2024

SOPHiA GENETICS launches residual acute myeloid application for post-remission monitoring

Product updates

  • SOPHiA GENETICS has launched the residual acute myeloid (RAM) Application to its SOPHiA DDM platform. The new solution strengthens the company's oncology portfolio with measurable residual disease (MRD) testing capabilities.

  • The RAM Application uses next-generation sequencing (NGS) technology, for post-remission monitoring and identifying early relapse in acute myeloid leukemia (AML) patients. This application leverages the analytical capabilities of the SOPHiA DDM Platform. It is claimed to enable sensitive variant detection down to 0.01% VAF, covering guideline-recommended genes to deliver insights for residual acute myeloid. The solution also offers customizable reporting features and comprehensive MRD reports and leverages machine learning for accurate results within four days.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.